
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Therapeutics is well-equipped to enter the gene therapy market for bladder cancer with its innovative product, detalimogene, which addresses the limitations of current treatments. However, the reliance on contract manufacturers and potential for supply chain challenges may impact the success of their product. The company has a strong financial outlook and experienced leadership, but faces regulatory obstacles and competition in the growing immunotherapy market. Overall, enGene Therapeutics shows potential for growth and success in the future.
Bears say
enGene Therapeutics is facing several challenges that could adversely affect its growth and financial stability, including the need for additional capital, potential competition in the non-muscle invasive bladder cancer (NMIBC) space, and potential safety concerns with its lead product candidate, detalimogene. Additionally, unexpected regulatory changes or competition from other gene therapy companies could hinder enGene's ability to gain market traction. The fact that enGene became publicly traded through a SPAC also adds uncertainty to its future performance. Considering these risks and challenges, there is a negative outlook on enGene Therapeutics' stock.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares